Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Orthocell Ltd ( (AU:OCC) ) has provided an update.
Orthocell Ltd has expanded its distribution network in Canada by appointing a second distributor for its nerve repair device, Remplir™, achieving full national coverage in the US$75 million Canadian market. This strategic move enhances Orthocell’s market penetration, with first sales expected this quarter following a successful launch at a major medical conference. The new distributor, based in Ontario, will cover provinces outside Alberta and British Columbia, leveraging extensive experience in the nerve, spine, and orthopedic sectors. This expansion is part of Orthocell’s broader strategy to drive sales and establish strong distributor relationships globally, supported by a robust financial position and existing marketing and education teams.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Ltd is a company in the medical device industry, specializing in nerve repair solutions. Their primary product, Remplir™, is a flagship nerve repair medical device, with a focus on expanding its market presence in North America and other global regions.
Average Trading Volume: 748,738
Technical Sentiment Signal: Buy
Current Market Cap: A$322.3M
See more insights into OCC stock on TipRanks’ Stock Analysis page.